Safety, immunogenicity and efficacy of intranasals, live attenuated influenza vaccine

Expert Review of Vaccines

Volumn 3, Issue 6, 2004, Pages 643-654

  Belshe, Robert ^a   Lee, Min Shi ^b   Walker, Robert E ^b   Stoddard, Jeffrey ^b   Mendelman, Paul M ^b  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MEDIMMUNE   (United States)

Author keywords

Intranasal; Live attenuated influenza vaccine

Indexed keywords

HEMAGGLUTINATION INHIBITING ANTIBODY; INFLUENZA VACCINE; LIVE VACCINE; SECRETORY IMMUNOGLOBULIN;

ADOLESCENT; ADULT; ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; GENETIC STABILITY; HIGH RISK POPULATION; HUMAN; IMMUNOGENICITY; INFECTION PREVENTION; INFLUENZA; INFLUENZA VACCINATION; INFLUENZA VIRUS; MAJOR CLINICAL STUDY; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SIDE EFFECT; VIRUS CULTURE; VIRUS REPLICATION; VIRUS TRANSMISSION;

ADMINISTRATION, INTRANASAL; ADOLESCENT; ADULT; AGE FACTORS; CHILD; CHILD, PRESCHOOL; HUMANS; IMMUNITY, NATURAL; INFLUENZA A VIRUS; INFLUENZA B VIRUS; INFLUENZA VACCINES; INFLUENZA, HUMAN; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS; VACCINES, ATTENUATED;

EID: 9644266748     PISSN: 14760584     EISSN: None     Source Type: Journal    
DOI: 10.1586/14760584.3.6.643     Document Type: Article

References (64)

1. Belshe RB, Gruber WC. Prevention of otitis media in children with live attenuated influenza vaccine given intranasally. Ped. Infect. Dis. J. 19, S66-S71 (2000).
2. Prevention and control of influenza. Morb. Mortal. Weekly Rep. 53, 1-40 (2004).
3. Belshe RB, Mendelman PM, Treanor J et al. The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine in children. N. Engl. J. Med. 338, 11405-11412 (1998).
4. Belshe RB, Gruber WC, Mendelman PM et al. Efficacy of vaccination with live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine against a variant (A/Sydney) not contained in the vaccine. J. Ped. 136, 168-175 (2000).
5. Belshe RB, Gruber WC, Mendelman PM et al. Correlates of immune protection induced by live attenuated, cold-adapted, trivalent intranasal influenza virus vaccine. J. Infect. Dis. 181, 1133-1137 (2000).
6. Nichol KL, Mendelman PM, Mallon KP et al., for the Live Attenuated Influenza Virus Vaccine in Healthy Adults Trial Group. Effectiveness of live, attenuated intranasal influenza virus vaccine in healthy, working adults: a randomized controlled trial. JAMA 282, 137-145 (1999).
7. Gaglani MJ, Piedra PA, Herschler GB et al. Direct and total effectiveness of the intranasal, live attenuated, trivalent cold-adapted influenza virus vaccine against the 2000-2001 influenza A(H1N1) and B epidemic in healthy children. Arch. Pediatr. Adolesc. Med. 158, 65-73 (2004).
8. Halloran ME, Longini IM Jr, Gaglani MJ et al. Estimating efficacy of trivalent, cold-adapted, influenza virus vaccine (CATV-T) against influenza A (H1N1) and B using surveillance cultures. Am. J. Epidemiol. 158, 305-311 (2003).
9. Piedra PA, Van L, Kotloff K et al. Safety of the trivalent, cold-adapted influenza vaccine (CAIV-T) in preschool aged children. Pediatrics 110, 662-672 (2002).
10. Maassab HF. Biologic and immunologic characteristics of cold-adapted influenza virus. J. Immunol. 102, 728-732 (1969).
11. Jin H, Lu B, Zhou H et al. Multiple amino acid residues confer temperature sensitivity to human influenza virus vaccine strains (FluMist) derived from cold-adapted A/Ann Arbor/6/60. Virology 306, 18-24 (2003).
12. Hoffmann E, Mahmood K, Yang CF et al. Molecular basis for temperature sensitivity and attenuation of the human vaccine strain B/Ann Arbor/1/66. Options for the Control of Influenza V Conference. Okinawa, Japan, Abstract WO7P-51 (2003).
13. Donabedian AM, DeBorde Dc, Maassab HF. Genetics of cold-adapted B/Ann Arbor/1 /66 influenza virus reassortants: the acidic polymerase (PA) protein gene confers temperature sensitivity and attenuated virulence. Microb. Pathog. 3, 97-108 (1987).
14. Maassab HF, Heilman CA, Herlocher ML. Cold-adapted influenza viruses for use as live vaccines for man. Adv. Biotechnol. Proces. 14, 203-242 (1990).
15. Cox NJ, Maassab HF, Kendal AP. Comparative studies of wild-type and cold-mutant (temperature-sensitive) influenza viruses: nonrandom reassortment of genes during preparation of live virus vaccine candidates by recombination at 25° between recent H3N2 and H1N1 epidemic strains and cold-adapted A/Ann Arbor/6/10. Virology 190-194 (1979).
16. Maassab HF, Kendal AP, Abrams GD, Monto AS. Evaluation of cold-recombinant influenza virus vaccine in ferrets. J. Infect. Dis. 146, 780-790 (1982).
17. Glezen WP, Keitel WA, Taber LH et al. Age distribution of patients with medically-attended illnesses caused by sequential variants of influenza A/H1N1: comparison to age-specific infection rates, 1978-1989. Am. J. Epidemiol. 133, 296-304 (1991).
18. Hoskins TW, Davies JR, Smith AJ, Miller CL, Allchin A. Assessment of inactivated influenza-A vaccine after three outbreaks of influenza A at Christ's Hospital. Lancet 1, 33-35 (1979).
19. Davies JR. Grilli EA. Natural or vaccine-induced antibody as a predictor of immunity in the face of natural challenge with influenza viruses. Epidemiol. Infect. 102, 325-333 (1989). (Erratum appears in Epidemiol. Infect. 103, 217 [1989]).
20. Davies JR. Grilli EA. Natural or vaccine-induced antibody as a predictor of immunity in the face of natural challenge with influenza viruses. Epidemiol. Infect. 102, 325-333 (1989). (Erratum appears in Epidemiol. Infect. 103, 217 [1989]).
21. European Medicines Evaluation Agency. Note for guidance on harmonization of requirements for influenza vaccines. European Medicines Evaluation Agency, London, UK (1997).
22. Potter CW. Determinants of immunity to influenza infection in man. Br. Med. Bull. 335, 69-75 (1979).
23. National Institutes of Health. Specific immunity in influenza B summary of influenza workshop III. J. Infect. Dis. 127, 220-236 (1973).
24. Fox JP, Cooney MK, Hall CE, Hjordis MF. Influenza virus infections in Seattle families, 1975-1979. Am. J. Epidemiol. 116, 228-242 (1982).
25. Hjordis MF, Cooney MK, McMahan R, Bor E, Grayston JT. Single-dose monovalent A2/Hong Kong influenza vaccine efficacy 14 months after immunization. JAMA 217, 1067-1071 (1971).
26. Hoskins TW, Davies JR, Smith AJ et al. Influenza at Christ's Hospital: March 1974. Lancet 1, 105-108 (1976).
27. Murphy BR, Clements ML. The systemic and mucosal immune response of humans to influenza A virus. Curr. Topics Microbiol. Immunol. 146, 107-116(1989).
28. Gorse GJ, Belshe RB. Enhancement of anti-influenza A virus cytotoxicity following influenza A virus vaccination in older, chronically ill adults. J. Clin. Microbiol. 28, 2539-2550 (1990).
29. Halloran ME, Longini IM Jr, Gaglani MJ et al. Estimating efficacy of trivalent, cold-adapted, influenza virus vaccine (CATV-T) against influenza A (H1N1) and B using surveillance cultures. Am. J. Epidemiol. 158, 305-311 (2003).
30. Lee MS, Mahmood K, Adhikary L et al. Measuring antibody responses to a live-attenuated influenza vaccine in children. Pediatr. Infect. Dis. J. (2004). In press.
31. Mendelman PM, Rappaport R, Cho I et al. Live-attenuated influenza vaccine induces crossreactive antibody responses in children against an A/Fujian/411/2002-like H3N2 antigenic variant strain. Pediatr. Infect. Dis. J. 23, 1-3 (2004).
32. Treanor JJ, Kotloff K, Betts RF et al. Evaluation of trivalent, live, cold-adapted (CATV-T) and inactivated (TTV) influenza vaccines in prevention of virus infection and illness following challenge of adults with wild type influenza A (H1N1), A (H3N2), and B viruses. Vaccine 899-906 (2000).
33. King JC, Lagos R, Bernstein DI et al. Safety and immunogenicity of low and high doses of trivalent live cold-adapted influenza vaccine administered intranasally as drops or spray to healthy children. J. Infect. Dis. 177, 1394-1397 (1998).
34. Bernstein DI, Van L, Treanor J, Mendelman PM, Belshe R. Cold-adapted, trivalent, influenza vaccine study group. Effect of yearly vaccinations with live, attenuated, cold-adapted, trivalent, intranasal influenza vaccines on antibody responses in children. Pediatr. Infect. Dis. J. 22, 28-34 (2003).
35. Gorse GJ, O'Connor TZ, Newman FK et al. Immunity to influenza in older adults with chronic obstructive pulmonary disease. J. Infect. Dis. 190, 11-19 (2004).
36. Gruber WC, Belshe RB, King JC et al. Evaluation of live attenuated influenza vaccines in children 6-18 months of age: safety, immunogenicity, and efficacy. J. Infect. Dis. 173, 1313-1319 (1996).
37. Nolan T, Lee MS, Cordova JM et al. Safety and immunogenicity of a live-attenuated influenza vaccine blended and filled at two manufacturing facilities. Vaccine 21, 1224-1231 (2003).
38. Bridges CB, Thompson WW, Meltzer MI et al. Effectiveness and cost benefit of influenza vaccination of healthy working adults: a randomized controlled trial. JAMA 284, 1655-1663 (2000).
39. Edwards KM, DuPont WD, Westrich MK et a. A randomized controlled trial of cold-adapted and inactivated vaccines for the prevention of influenza A disease. J. Infect. Dis. 169, 68-76 (1994).
40. Clover RD, Crawford S, Glezen WP et al. Comparison of heterotypic protection against influenza A/Taiwan/86 (H1N1) by attenuated and inactivated vaccines to A/Chile/83-like viruses. J. Infect. Dis. 163, 300-304 (1991).
41. Bridges CB, Thompson WW, Meltzer MI et al. Effectiveness and cost benefit of influenza vaccination of healthy working adults: a randomized controlled trial. JAMA 284, 1655-1663 (2000).
42. Tam JS, Capeding MR, Lum LCS et al. Efficacy of a live attenuated influenza vaccine (CAIV-T) in children living in Southeast Asia against community-acquired culture-confirmed influenza. Options for the Control of Influenza V. Okinawa, Japan, Abstract W03P-05 (2003).
43. Vesikari T, Aristegui JF, Ashkenazi S and et al. Efficacy of a live attenuated influenza vaccine in children aged 6 to < 36 months attending day care centers in Europe and Israel against community-acquired culture-confirmed influenza. Options for the control of influenza V. Okinawa, Japan, Abstract W07-5 (2003).
44. Ashkenazi S, Vertruyen A, Aristegui J et al. Comparison of safety and efficacy of a trivalent live attenuated, intranasal influenza vaccine (CAIV-T) with trivalent inactivated intramuscular influenza vaccine (TIV) in children aged 6 to <72 months with a history of respiratory tract infections. Pediatric Academic Societies Annual Meeting. San Francisco, CA, USA, Abstract LB7 (2004).
45. Fleming D, Crovari P, Wahn U et al. Comparison of safety and efficacy of a trivalent live attenuated, intranasal influenza vaccine (CAIV-T) with trivalent inactivated intramuscular influenza vaccine (TIV) in children and adolescents aged 6 to <18 years with asthma. Pediatric Academic Societies Annual Meeting, CA, USA, Abstract LB20 (2004).
46. Bergen R, Black S, Shinefield H et al. Safety of cold-adapted live attenuated influenza vaccine in a large cohort of children and adolescents. Pediatr. Infect. Dis. J. 23, 138-144 (2004).
47. Redding G, Walker RE, Hessel C et al. Safety and tolerability of cold-adapted influenza virus vaccine in children and adolescents with asthma. Pediatr. Infect. Dis. J. 21, 44-48(2002).
48. Jackson LA, Holmes SJ, Mendelman PM et al. Safety of a trivalent live attenuated intranasal influenza vaccine, FluMist, administered in addition to parenteral trivalent inactivated influenza vaccine to seniors with chronic medical conditions. Vaccine 17, 1905-1909 (1999).
49. Treanor JJ, Mattison HR, Dumyati G et al. Protective efficacy of combined live intranasal and inactivated influenza A virus vaccines in the elderly. Ann. Int. Med. 117, 625-633 (1992).
50. Gorse GJ, O'Connor TZ, Young SL et al. Efficacy trial of live, cold-adapted and inactivated influenza virus vaccines in older adults with chronic obstructive pulmonary disease: a VA cooperative study. Vaccine 21, 2133-2144 (2003).
51. King JC Jr, Treanor J, Fast PE et al. Comparison of the safety, vaccine virus shedding, and immunogenicity of influenza virus vaccine, trivalent, types A and B, live cold-adapted, administered to human immunodeficiency virus (HIV)-infected and non-HIV-infected adults. J. Infect. Dis. 181, 725-728 (2000).
52. King JC Jr, Fast PE, Zangwill KM et al., the HIV Influenza Study Group. Safety, vaccine virus shedding and immunogenicity of trivalent, cold-adapted, live attenuated influenza vaccine administered to human immunodeficiency virus-infected and noninfected children. Pediatr. Infect. Dis. J. 10, 1124-1131 (2001).
53. Cha T-A, Kao K, Zhao J et al. Genotypic stability of cold-adapted influenza virus vaccine in an efficacy clinical trial. J. Clin. Microbiol. 38, 839-845 (2000).
54. Belshe RB, Van Voris LP. Cold-recombinant influenza A/California/10/78 (H1N1) virus vaccine (CR-37) in seronegative children: infectivity and efficacy against investigational challenge. J. Infect. Dis. 149, 735-740 (1984).
55. Clements ML, Snyder MH, Sears SD et al. Evaluation of the infectivity, immunogenicity, and efficacy of live cold-adapted influenza B/Ann Arbor/1/86 reassortant virus vaccine in adult volunteers. J. Infect. Dis. 161, 869-877 (1990).
56. Couch RB, Quarles JM, Gate TR et al. Clinical trials with live cold-reassortant influenza virus vaccines. In: Options for the Control of Influenza. Kendal AP, Patriarca PA (Eds). Alan R Liss, Inc., NY, USA, 223-241 (1986).
57. Davenport FM, Hennessy AV, Minuse E et al. Pilot studies on mono- and bivalent live attenuated influenza virus vaccines. Proceedings of the Symposium on Live Influenza Vaccine 105-113 (1971).
58. Davenport FM, Hennessy AV, Maassab HF et al. Pilot studies on recombinant cold-adapted live Type A and B influenza virus vaccines. J. Infect. Dis. 136, 17-25 (1977).
59. Moritz AJ, Kunz C, Hofman H et al. Studies with a cold-recombinant A/Victoria/3/75 (H3N2) virus. II. Evaluation in adult volunteers. J. Infect. Dis. 142, 857-860 (1980).
60. Reeve P, Gerendas B, Moritz A et al. Studies in man with cold-recombinant influenza virus (H1N1) live vaccines. J. Med. Virol. 6, 75-83 (1980).
61. Van Voorthuizen F, Jens D, Saes F. Characterization and clinical evaluation of live influenza A vaccine prepared from a recombinant of the A/USSR/92/77 (H1N1) and the cold-adapted A/Ann Arbor/6/60 (H2N2) strains. Antiviral Res. 1, 107-122 (1981).
62. Wright PF, Okabe N, McKee KT Jr et al. Cold-adapted recombinant influenza A virus vaccines in seronegative young children. J. Infect. Dis. 146, 71-79 (1982).
63. Wright PF, Johnson PR, Karzon DT. Clinical experience with live, attenuated vaccines in children. In: Options for the Control of Influenza. Kendal AP, Patriarca PA (Eds). Alan R Liss, Inc., NY, USA, 243-253 (1986).
64. Vesikari T, Karvonen A, Korhonen T et al. A randomized, double-blind, placebo-controlled trial of the safety, transmissibility and phenotypic stability of a live, attenuated, cold-adapted influenza virus vaccine (CAIV-T) in children attending day care. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), IL, USA, Abstract G-450 (2001).